Ken Fisher

Ken Fisher

Last Update: 01-27-2017

Number of Stocks: 729
Number of New Stocks: 58

Total Value: $55,303 Mil
Q/Q Turnover: 2%

Countries: USA CAN
Details: Top Buys | Top Sales | Top Holdings  Embed:

Ken Fisher Watch

  • Is Williams-Sonoma a Better Bargain Than Ever?

    (Published by Nicholas McCullum on March 19)


    The retail sector has been under pressure for some time now.

      


  • Ray Dalio's Top 10 Holdings Include Giant Apple

    Ray Dalio (Trades, Portfolio)'s Bridgewater Associates disclosed an equity portfolio valued at some $10.53 billion at the end of the fourth quarter of 2016 and a top 10 concentration of 83.2%.


    In this article, we will look into the eighth top holding held at the end of the fourth quarter: Apple Inc. (NASDAQ:AAPL).

      


  • Executive Chairman Slashes Stake in Gilead Sciences

    Insider John Martin, the executive chairman of Gilead Sciences (NASDAQ:GILD), sold 73,333 shares on March 3 for $70.38 per share according to a Form 4 filing with the securities and exchange commission


    Gilead Sciences has a market cap of $88.72 billion, a price-earnings (P/E) ratio of 6.83, an enterprise value of $103.65 billion and a price-book (P/B) ratio of 4.71.

      


  • Despite Disappointing Short-Term Results, FedEx Is Leading the Way

    Expansion and cost advantage


    As a leader in global express delivery, FedEx Corp. (NYSE:FDX) continues to focus on growth opportunities outside the U.S. The company is keeping pace with the rapid rate of expansion into developing markets like China. Another advantage is the fact volumes provide a cost advantage over new competitors. On the other hand, FedEx operates in a highly capital-intensive industry. For example, air freighter replenishment will need heavy capital expenditures in the next several years.

      


  • Parexel Investors: Swimming With the Whales

    Biopharm outsourcing company Parexel has a lot—a whole lot—of institutional ownership. GuruFocus reports that pension mutual funds and other big buyers and sellers own more than 99% of the company.


    Parexel International Corp. (PRXL) is a major biopharmaceutical outsourcing services company; its main line of business is helping drug companies navigate their way through clinical trials to (hopefully) regulatory approval. It says it has been involved in developing 95% of the 200 top-selling biopharmaceuticals.

      


  • Chase Coleman Exits Apple, Cuts MasterCard, Alphabet

    Chase Coleman (Trades, Portfolio) is the founder of Tiger Global Management. He manages a portfolio composed of 37 stocks with a total value of $8.031 billion. During the fourth quarter the guru sold shares in the following stocks.


    The investor closed his stake in Apple Inc. (AAPL) with an impact of -5.87% on the portfolio.

      


  • AbbVie Regimen Recommended for HCV Infection

    AbbVie Inc. (NYSE:ABBV) communicated through the PRNewswire Monday that it received a positive feedback from the European Committee for Medicinal Products for Human Use (CHMP) about the possibility of using VIEKIRAX plus EXVIERA in a combined therapy of eight weeks to treat chronically genotype 1b HCV-infected adult patients.


    These patients are naïve to any kind of HCV treatment, and their liver shows some scar tissue forms from minimal to moderate. Therefore, they are noncirrhotic yet.

      


  • 7 Undervalued Stocks With Growing EPS

    Companies with growing earnings per share (EPS) are often good investments as they can return a good profit to investors. Here is a selection of the most undervalued companies, according to the DCF calculator, that have a five-year growing EPS.


    EPS of Ever-Glory International Group Inc. (EVK) grew by 17% over the last 10 years.

      


  • Jeff Ubben Nabs NetScout in 4th Quarter

    ValueAct Capital founder Jeff Ubben (Trades, Portfolio) gained one new holding in the final quarter of 2016, NetScout Systems Inc. (NASDAQ:NTCT).


    Ubben founded ValueAct in 2000 and serves as the CEO and chief investment officer. He manages a concentrated portfolio composed of companies he believes are fundamentally undervalued or out of favor. He generally establishes a significant ownership stake in order to work with management on maximizing returns to shareholders. His current portfolio consists of 14 stocks and is valued at $12.17 million.

      


  • Ken Fisher for Forbes: For Defense Investments, Think Smaller And Cheaper

    Big defense contractors tanked the week after Trump won the election. The Republicans won’t get blamed for being too soft on defense, so they needn’t be strong on it. And as we’ve seen, Trump won’t like big firms charging him big-ticket prices.


    If you’re doing defense, think smaller, cheaper and diversified, such as Textron, (NYSE:TXT) led by its smaller, cheaper Cessna line of planes, bought by defense and nondefense customers alike.

      


  • 3M Insider Sells Holdings in Company

    3M Co. (MMM) Chairman, President and CEO Inge Thulin (Insider Trades) sold 28,183 shares for $177.48 per share on Feb. 9. The total transaction was $5,001,919.


    3M designs and manufactures products to make everyday life more efficient. The company has a market cap of $106.86 billion.

      


  • 7 High-Yield Stocks With a Negative 1-Year Performance

    According to the GuruFocus All-in-One Screener, the following stocks have a high dividend yield but performed poorly over the past 12 months.


    Cal-Maine Foods Inc.’s (NASDAQ:CALM) dividend yield is now 2.84% with a payout ratio of 6.27%. Over the past 52 weeks however, the stock's price dropped 12.8% and it is now trading with a  price-earnings (P/E) ratio of 210.3 and a price-sales (P/S) ratio of 1.6.

      


  • FDA Approves Abbott Labs' Devices for MRI Scans

    Good news for heart patients implanted with Abbott Labs’ (NYSE:ABT) Assurity MRI pacemaker and Tendril MRI pacing lead. The U.S. Food and Drug Administration (FDA) has approved the two devices for total-body MRI scans.


    This means that heart patients with an Assurity MRI pacemaker or Tendril MRI pacing lead implanted can “undergo full-body magnetic resonance imaging (MRI) scans, if required,” Abbott announced.

      


  • Valero Energy Reports 2016 Results

    Valero Energy Corp. (NYSE:VLO) released its results for fourth-quarter and full-year 2016 on Jan. 31, reporting an earnings beat.


    For the fourth quarter, Valero generated EPS of 81 cents, beating expectations  by four cents. The difference between the actual EPS and the estimated EPS generated a positive surprise of 5.20%.

      


  • Beware Apple for Early 2017

    On Jan. 31, 2017, Apple Inc. (NASDAQ:AAPL) reported revenue of $78.4 billion and earnings per share of $3.36 for their fiscal first-quarter 2017. These values outperformed fiscal first-quarter 2016 values, implying that the Cupertino-based consumer electronics company started their fiscal year strong. Despite the strong performance, Apple’s financial outlook is expected to decline for fiscal second-quarter 2017.


    Brief summary of earnings report

      


  • Shuffling the Business Mix Pays Off for NICE

    It was a significant business decision for NICE-Systems Ltd. (NASDAQ:NICE) to drop two major lines and focus instead on the remaining two: customer interaction (such as call center software) and financial fraud prevention.


    Yet it has worked out well for this Israel-based information technology company, which has consistently grown its top and bottom lines.

      


  • 6 Low P/E Stocks Gurus Are Buying

    Here are six stocks gurus are buying that are trading with low price-earnings (P/E) ratios. Some of them are great investments; others need a double check, according to the DCF calculator.


    Infosys Ltd. ADR (INFY) with a market cap of $31.86 billion is trading with a P/E ratio of 14.84 and a price-sales (P/S) ratio of 3.14. According to the DCF calculator the stock has a fair value of $21.5 while trading at about $13.94. The price has dropped by 22% during the last 12 months and is now 31.90% below its 52-week high and 1.46% above its 52-week low.

      


  • Microsoft Finishes 2016 Strong

    During fourth-quarter 2016, Microsoft Corp. (NASDAQ:MSFT) reported net income of $5.2 billion and diluted earnings per share of 66 cents on an as-reported basis. Adjusting for Windows 10 revenue deferrals, net income increased to $6.515 billion while earnings per share climbed to 83 cents. Both performance figures outperformed comparative values for fourth-quarter 2015, suggesting Microsoft had a strong final quarter of 2016 and expects a good financial outlook for 2017.


    Brief summary of earnings report

      


  • All-In-One Screener Finds Companies With High, Growing Yields

    Thanks to GuruFocus’ All-In-One Screener, we can pinpoint stocks that have a five-year growing dividend yield with strong profitability and a long-term track of solid returns and growing asset value.


    Equifax Inc.’s (EFX) dividend yield has grown by 28% over the last five years. The yield is now 1.12% with a payout ratio of 32%. The company has a 10-year asset growth rate of 9% supported by an average return on assets (ROA) of 7.88%.

      


  • 6 Stocks Trading Below Peter Lynch Value

    According to the GuruFocus All-in-One Screener, several gurus are focusing on stocks whose Peter Lynch fair values are far above the current price. The following stocks are trading with wide margins of safety and at least five gurus are shareholders.


    Morgan Stanley (NYSE:MS) is trading around $43 per share. The Peter Lynch value gives the stock a fair price of $61.72, so the stock is undervalued with a margin of safety of 30%.

      


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)